Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Nivolumab in Advanced Hepatocellular Carcinoma
NCT03439891Phase 2Completed
- Start
- Apr 2018
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in hepatocellular carcinoma (HCC). Started Apr 2018; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03439891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439891.